多発性骨髄腫のインド市場の評価：薬剤クラス別、疾患タイプ別、流通チャネル別、地域別、機会、予測（2019年度～2033年度）

インドの多発性骨髄腫の市場規模は、2025年度の1億9,208万米ドルから2033年度に3億3,625万米ドルに達すると予測され、2026年度～2033年度の予測期間にCAGRで7.25%の成長が見込まれます。市場は、血液がんの有病率の上昇と啓発活動の活発化により急成長を示しています。抗CD38モノクローナル抗体のような標的治療薬の進歩により、治療成績が向上し、患者のアクセスも拡大しています。さらに、南インドにおける医療インフラの強化が、この地域の市場成長をさらに後押ししています。

例えば、デリーのAIIMSの医療従事者は現在、血液がんの一種である多発性骨髄腫の治療を目的とした、安価な抗体ベースの適応性のある細胞療法の開発に取り組んでいます。この革新的な治療法は、インドの患者にとってCAR-T細胞療法などの先進の治療法の入手性や利用しやすさを向上させると予測されます。

当レポートでは、インドの多発性骨髄腫市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 インドの多発性骨髄腫市場の見通し（2019年度～2033年度）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 薬剤クラス別
    • 免疫調節薬
    • プロテアソーム阻害薬
    • 抗CD38モノクローナル抗体
    • アルキル化剤
    • その他
  • 疾患タイプ別
    • 活動性多発性骨髄腫
    • くすぶり型多発性骨髄腫
  • 流通チャネル別
    • 病院薬局
    • 小売薬局・ドラッグストア
    • オンライン薬局
  • 地域別
    • 北部
    • 東部
    • 西部・中部
    • 南部
  • 市場シェア分析：企業別（上位5社とその他 - 金額、2025年度）
• 市場マップ分析（2025年度）
  • 薬剤クラス別
  • 疾患タイプ別
  • 流通チャネル別
  • 地域別

第6章 需給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第14章 特許情勢

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Novartis Healthcare Private Limited
  • Cipla Limited
  • NATCO Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Zydus Lifesciences Limited
  • Emcure Pharmaceuticals Limited
  • Biocon Limited
  • Hetero Labs Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Multiple Myeloma Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. India Multiple Myeloma Market Share (%), By Drug Class, FY2019-FY2033F
• Figure 3. India Multiple Myeloma Market Share (%), By Disease Type, FY2019-FY2033F
• Figure 4. India Multiple Myeloma Market Share (%), By Distribution Channel, FY2019-FY2033F
• Figure 5. India Multiple Myeloma Market Share (%), By Region, FY2019-FY2033F
• Figure 6. By Drug Class Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 7. By Disease Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 8. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

India multiple myeloma market is projected to witness a CAGR of 7.25% during the forecast period FY2026-FY2033, growing from USD 192.08 million in FY2025 to USD 336.25 million in FY2033. The India multiple myeloma market is witnessing rapid growth due to the rising prevalence of blood cancers and increasing awareness initiatives. Advancements in targeted therapies like anti-CD38 monoclonal antibodies are improving treatment outcomes and expanding patient access. Additionally, the strengthening healthcare infrastructure in South India is further propelling regional market growth.

For example, medical professionals at AIIMS, Delhi are currently working on creating an affordable antibody-based adaptive cellular therapy aimed at treating multiple myeloma, a type of blood cancer. This innovative therapy is anticipated to enhance the affordability and accessibility of advanced treatments such as CAR-T cell therapies for patients in India.

Rising Cancer Prevalence and Growing Awareness to Accelerate Market Growth

The increasing incidence of blood cancers, particularly multiple myeloma, is a major factor fueling market expansion in India. Multiple myeloma often remains underdiagnosed in earlier stages; however, with enhanced public health awareness, early diagnosis rates are improving. Additionally, educational campaigns initiated by hospitals and healthcare organizations are promoting awareness about hematological malignancies, leading to higher demand for advanced therapies. The growing healthcare expenditure and the expanding network of cancer specialty centers are also contributing to broader treatment accessibility. These factors are creating a robust environment for the adoption of novel drug classes like immunomodulators and proteasome inhibitors. For instance, in August 2024, the Kidwai Memorial Institute of Oncology in Bangalore (KMIO) organized 'Myeloma Matters: An International Symposium on Multiple Myeloma' to discuss the challenges and advancements in the treatment of patients.

Advancements in Anti-CD38 Monoclonal Antibody Therapies Driving Market Expansion

The segment of anti-CD38 monoclonal antibody therapies is witnessing significant growth in India's multiple myeloma market. These therapies have shown greater effectiveness and improved patient outcomes when compared to conventional treatment methods, especially in cases of relapsed or refractory multiple myeloma. Indian pharmaceutical firms are increasingly dedicating efforts to the research, development, and marketing of biosimilars and generics aimed at CD38, thereby improving affordability and access. Furthermore, the Indian Council of Medical Research (ICMR) has emphasized monoclonal antibody therapies in its revised treatment protocols for multiple myeloma, which is expected to enhance the adoption of this segment. For instance, Dr. Reddy's Laboratories, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., announced a licensing agreement in February 2025 with Shanghai Henlius Biotech, Inc. for the development and commercialization of HLX15, Henlius's investigational biosimilar candidate for daratumumab, marketed as Darzalex(R) and Darzalex Faspro(R).

Strong Regional Growth in South India Due to Rising Healthcare Infrastructure

The southern region of India, especially Tamil Nadu and Karnataka, is becoming a significant area of growth for the multiple myeloma market. This region features a sophisticated healthcare system, heightened patient awareness, and a multitude of specialized cancer hospitals that provide innovative treatment options. Furthermore, the rise in healthcare investments from both state governments and the private sector is enhancing cancer care services. South India's prompt adoption of advanced treatments, such as immunotherapies and targeted biologics, is propelling the expansion of the multiple myeloma pharmaceutical market. A notable advancement in oncology care is the establishment of India's first AI-Precision Oncology Centre (POC) at Apollo Cancer Centre in Bengaluru, which aims to support oncologists, patients, and caregivers in achieving optimal treatment outcomes through the effective use of artificial intelligence.

Future Market Scenario (FY2026 - FY2033F)

India multiple myeloma market is expected to witness robust growth in the coming years, driven by increasing disease awareness, rising healthcare spending, and the growing availability of innovative treatment options. Advances in targeted therapies, such as anti-CD38 monoclonal antibodies and proteasome inhibitors, are improving patient outcomes and expanding treatment accessibility. Furthermore, government initiatives to enhance cancer care infrastructure and early diagnosis programs are strengthening market dynamics. Collaborations between domestic and international pharmaceutical companies to develop biosimilars and affordable therapies will also significantly contribute to market expansion. With a rising elderly population and greater emphasis on specialized oncology centers, the India multiple myeloma market is poised for substantial growth, offering new opportunities for pharmaceutical innovation and patient care advancement.

Key Players Landscape and Outlook

Key players in the multiple myeloma industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, in a major advancement for cancer treatment, PGI is set to commence clinical trials of CAR T-cell therapy for patients with multiple myeloma. This initiative is part of a broader national effort and provides renewed hope for those fighting cancer. The ethics committee has granted approval for the trials at the institute, which is one of the locations involved in the multi-centric study.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. India Multiple Myeloma Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. Immunomodulators
    • 5.2.1.2. Proteasome Inhibitor
    • 5.2.1.3. Anti-CD38 Monoclonal Antibody
    • 5.2.1.4. Alkylating Agents
    • 5.2.1.5. Others
  • 5.2.2. By Disease Type
    • 5.2.2.1. Active Multiple Myeloma
    • 5.2.2.2. Smoldering Multiple Myeloma
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies and Drug Stores
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. North
    • 5.2.4.2. East
    • 5.2.4.3. West and Central
    • 5.2.4.4. South
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Drug Class
  • 5.3.2. By Disease Type
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis Healthcare Private Limited
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Cipla Limited
  • 16.3.3. NATCO Pharma Limited
  • 16.3.4. Dr. Reddy's Laboratories Ltd.
  • 16.3.5. Sun Pharmaceutical Industries Ltd.
  • 16.3.6. Lupin Limited
  • 16.3.7. Zydus Lifesciences Limited
  • 16.3.8. Emcure Pharmaceuticals Limited
  • 16.3.9. Biocon Limited
  • 16.3.10. Hetero Labs Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer